Helix BioPharma Corp. has announced key leadership appointments aimed at advancing its mission to develop innovative treatments for hard-to-treat cancers. Veronika Kandziora joins the company as Chief Operating Officer, bringing over 20 years of leadership experience across biopharma, financial, and consulting sectors, while Dr. Jessica Kourniaktis assumes the role of Director of Communications.
Kandziora's appointment leverages her extensive background in corporate strategy, stakeholder engagement, and regulatory compliance. With previous roles including Corporate Secretary and strategic consultant for Helix, she brings deep institutional knowledge to her new position. Her experience spans international project management and asset management, with a particular focus on biotechnology.
Dr. Kourniaktis enters her communications role with a unique background combining academic research and industry leadership. Her experience includes founding a boutique consultancy, serving as COO for multiple biopharma startups, and previously advising clients in oncology and related scientific domains. Her strategic approach aims to enhance the company's narrative and stakeholder engagement.
CEO Thomas Mehrling emphasized the strategic importance of these appointments, noting that both executives will be critical in helping Helix navigate its next developmental phase. Their expertise is expected to strengthen the company's operational capabilities and communication strategies at a crucial time in its growth trajectory.
The appointments come as Helix continues to develop its pipeline of oncology treatments, with a particular focus on its lead candidate L-DOS47, an antibody-enzyme conjugate targeting CEACAM6-expressing solid tumors. The new leadership is positioned to support the company's mission of transforming hard-to-treat cancers through innovative therapeutic approaches.
